Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Hiroaki Akamatsu(Army Medical University), Nobuyuki Yamamoto(Wakayama Medical University), Junichi Shimizu(Aichi Cancer Center), Motoko Tachihara(Kobe University), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Hidetoshi Hayashi(Kindai University), Koichi Azuma(Kyushu University Hospital), Shunsuke Teraoka(Wakayama Medical University), Naoki Furuya(St. Marianna University School of Medicine), Daichi Fujimoto(Hyogo University), Yukihiro Toi(Sendai Kousei Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Satoshi Morita(Kyoto University), Naoko Miura(National Hospital Organization Kyushu Cancer Center), Satoshi Hara(Itami City Hospital), Nobuyuki Katakami(Takarazuka City Hospital), Sakiko Otani(Kitasato University)
Cited by 185
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k